Brincker H, Hansen H S, Andersen A P
Br J Cancer. 1973 Sep;28(3):232-7. doi: 10.1038/bjc.1973.142.
The records of 194 patients with thyroid carcinoma treated with (131)I, representing all cases thus treated in Denmark from 1948 to 1972, were reviewed. Two cases of myeloid leukaemia were found compared with 0·097 expected cases of non-lymphocytic leukaemia (0·05 > P > 0·01). In 5 series of (131)I treated thyroid carcinomata, 10 cases of myeloid leukaemia occurred in a total of 487 patients, corresponding to a frequency of leukaemia of about 2%. These findings appear to show that (131)I treatment of thyroid carcinoma is associated with a certain risk of development of leukaemia. This risk must be considered when treatment of localized thyroid carcinoma is planned.
回顾了194例接受碘-131治疗的甲状腺癌患者的记录，这些病例代表了1948年至1972年丹麦所有接受该治疗的患者。发现2例髓性白血病，而预期的非淋巴细胞白血病病例数为0.097例（0.05＞P＞0.01）。在5组接受碘-131治疗的甲状腺癌患者中，487例患者共出现10例髓性白血病，白血病发生率约为2%。这些发现似乎表明，碘-131治疗甲状腺癌与白血病发生的一定风险相关。在计划对局限性甲状腺癌进行治疗时，必须考虑这一风险。
